Orthocell Ltd (ASX:OCC, OTC:ORHHF) has unveiled promising interim results from a new study investigating the role of sutures in nerve repair, showing that its flagship Remplir product delivers superior outcomes compared with the traditional suture-only method.
The study, designed to support the company's US sales launch, highlights Remplir’s potential to redefine the nerve repair market, providing key data to bolster its ongoing global rollout.
Breakthrough results support Remplir's superiority
The suturing study, conducted in collaboration with Orthocell’s chief scientific officer, Professor Minghao Zheng, and the University of Western Australia, focused on evaluating the impact of sutures versus Remplir in the surgical repair of severed peripheral nerves. Results demonstrated that Remplir not only facilitated earlier functional recovery but also promoted superior nerve regeneration when compared to standard suture-based repair.
In the study, conducted on a rat sciatic nerve injury model, animals treated with Remplir showed significantly faster nerve function recovery and better tissue regeneration. In contrast, those treated with sutures alone exhibited severe inflammation and misalignment of nerve tissue, resulting in slower recovery and poorer quality regeneration.
Strategic advantages ahead of US sales launch
Orthocell CEO Paul Anderson was buoyed by the interim results, noting that the data will play a crucial role in the company’s efforts to secure rapid market adoption in the US, which represents a US$1.6 billion nerve repair market.
"We believe Remplir will redefine the nerve repair market and vastly improve the success of often-complex nerve repair surgery," Anderson said.
The study’s compelling outcomes will be highlighted at key medical conferences and form the foundation of Orthocell’s medical education strategy in the US.
The positive study results reinforce earlier clinical findings and support the growing market confidence in Remplir’s potential. Orthocell is currently progressing with the product’s US rollout, with the first sales expected soon following the recent US FDA clearance. The company has secured distributors in the US, expanding its network across 21 states and preparing for widespread market penetration.
Expanding global footprint and accelerating revenue generation
Orthocell’s growth trajectory is further supported by its robust cash reserves of about $30 million, ensuring the company is well-funded to drive Remplir’s global expansion. The successful commercialisation of Remplir is a critical part of its strategy to target the broader US$3.5 billion total addressable market for nerve repair.
The company has already made significant strides in securing its position in key global markets, with Hong Kong the latest market to grant approval for Remplir’s sale, underscoring Orthocell’s growing international footprint. In addition to the US and Hong Kong, Orthocell has secured regulatory approvals in Australia, New Zealand, Singapore, Thailand, and Canada, with plans for additional submissions in the EU, the UK and Brazil in the coming months.
As Orthocell prepares for the next phase of Remplir’s global rollout, the company remains focused on converting regulatory approvals into sales, targeting sustained revenue growth in the world’s largest nerve repair markets.